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Abstract 25 
 26 
Objectives: The emergence of MDR tuberculosis, coupled with shrinking antibiotic pipelines, 27 
has increased demands for new antimicrobials with novel mechanisms of action. Antimicrobial 28 
peptides have increasingly been explored as promising alternatives to antibiotics, but their 29 
inherent poor in vivo stability remains an impediment to their clinical utility. We therefore 30 
systematically evaluated unnatural amino acid modified peptides to design analogues with 31 
enhanced anti-mycobacterial activities.  32 
 33 
Methods:  Anti-mycobacterial activities were evaluated in vitro and intracellularly against 34 
drug-susceptible and MDR isolates of Mycobacterium tuberculosis using MIC, killing efficacy 35 
and intracellular growth inhibition studies. Toxicity profiles were assessed against mammalian 36 
cells to verify cell selectivity. Anti-mycobacterial mechanisms were investigated using 37 
microfluidic live-cell imaging with time-lapse fluorescence microscopy and confocal laser-38 
scanning microscopy. 39 
 40 
Results: Unnatural amino acid incorporation was well tolerated without an appreciable effect 41 
on toxicity profiles and secondary conformations of the synthetic peptides. The modified 42 
peptides also withstood proteolytic digestion by trypsin. The all D-amino acid peptide, i(llkk)2i 43 
(II-D), displayed superior activity against all six mycobacterial strains tested with a four-fold 44 
increase in selectivity index as compared to the unmodified L-amino acid peptide in broth. II-45 
D effectively reduced the intracellular bacterial burden of both drug-susceptible and MDR 46 
clinical isolates of M. tuberculosis after 4-days of treatment. Live-cell imaging studies 47 
demonstrated that II-D permeabilises the mycobacterial membrane, while confocal microscopy 48 
revealed that II-D not only permeates the cell membrane, but also accumulates within the 49 
cytoplasm.  50 
 51 
Conclusions: Unnatural amino acid modifications not only decreased the susceptibility of 52 
peptides to proteases, but also enhanced mycobacterial selectivity.  53 
 54 
Introduction 55 
 56 
According to the latest WHO figures, TB now ranks alongside HIV as the leading cause of 57 
death from an infectious disease worldwide, with 9.6 million new cases and 1.5 million deaths 58 
in 2014.1 Multidrug-resistant TB (MDR-TB) accounted for 3.3% of the new cases, 20% were 59 
previously treated cases, and 9.7% were extensively drug-resistant TB (XDR-TB). The WHO 60 
recently developed a new framework (The End TB Strategy) to succeed the Millennium 61 
Development Goals after 2015, aimed at reducing TB death and incidence rates by 95% and 62 
90% respectively.2 However, given that second-line drugs only cure 60% of MDR-TB and 40% 63 
of XDR-TB, resistant forms of Mycobacterium tuberculosis pose a significant challenge to 64 
global efforts in controlling TB.3 While two new drugs, bedaquiline and delamanid, have 65 
recently been approved for MDR-TB treatment, rifampicin was the last first-line drug to be 66 
developed in 1967. Currently, there are only eight new or repurposed drugs undergoing late 67 
phase clinical trials, of which few, if any may eventually make it to the clinic.1 Thus, it is 68 
crucial that a constant pipeline of novel anti-mycobacterial compounds is maintained to address 69 
these challenges and improve treatment outcomes.   70 
 71 
Antimicrobial peptides (AMPs) have gained prominence over the past few decades as a 72 
promising class of therapeutics, due to their potent broad-spectrum activity encompassing 73 
bacteria, fungi, viruses and parasites.4 Despite their structural diversity, AMPs possess key 74 
salient features including a net positive charge and a high proportion of hydrophobic residues, 75 
both of which are fundamental for AMP-mediated bacterial killing. Cationic AMPs adopt 76 
amphipathic structures upon contacting bacterial membranes, resulting in pore-formation via 77 
barrel-stave or toroidal-pore mechanisms, or widespread ‘micellization’ by carpet-like 78 
mechanisms.5 Alternatively, some peptides traverse the lipid bilayer, without inducing 79 
membrane permeabilisation, and inhibit enzymatic activity or impede cell wall, nucleic acid, 80 
or protein synthesis.5 Importantly, these bactericidal mechanisms are not limited to drug-81 
susceptible bacteria, but also target their drug-resistant counterparts including methicillin-82 
resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecalis,  MDR 83 
Pseudomonas aeruginosa and M. tuberculosis.6 In addition, the rapid membrane-lytic 84 
mechanisms of AMPs is likely to diminish their propensity for resistance development, while 85 
their ability to synergize with conventional antibiotics underlines their potential as adjuvants 86 
in combinatorial drug therapies for infection control.7 87 
 88 
However, the transition of AMPs from bench to bedside has largely been hindered by their 89 
susceptibility to enzymes in biological fluids and degradation by bacterial proteases, resulting 90 
in short half-lives and loss of antimicrobial properties.8 Several strategies have been employed 91 
to enhance AMP stability including the incorporation of unnatural amino acids, N- and/or C-92 
terminal modifications, cyclization, inclusion of non-peptidic backbones (peptidomimetics), 93 
and multimerization of AMP monomers to form dimers, oligomers and dendrimers.8 94 
Previously, D-enantiomers were studied to determine the influence of peptide chirality on 95 
function, and the importance of stereospecific interactions with enzymes, receptors or lipids in 96 
membranes.9, 10 While both L- and D-enantiomers of peptides emerged equally active, 97 
suggesting a lack of specific peptide-receptors interactions, the latter were more resistant to 98 
trypsin degradation. This in turn translated into longer half-lives in vivo, reinforcing their 99 
potential as therapeutic candidates.  100 
 101 
Increasing evidence suggests that incorporation of D-amino acids not only confers protection 102 
against proteolysis by trypsin, but also against bacterial proteases such as staphylococcal 103 
aureolysin and V8 proteinase, thus rendering peptides more active.11-13M. tuberculosis is also 104 
known to secrete enzymes such as proteases, lipases, esterases, and dehydrogenases, which 105 
contribute towards its pathogenicity and persistence in the host.14 However there are limited 106 
reports systematically evaluating the impact of various stability-enhancing modifications on 107 
the anti-mycobacterial activity of synthetic AMPs.15  108 
 109 
Recently, we demonstrated that the recurring sequence (XXYY)n – (where X is a hydrophobic 110 
amino acid, Y is a cationic amino acid, and n is the number repeat units) – could be used to 111 
design short amphipathic α-helical anti-mycobacterial peptides.16 Subsequently, N- and C-112 
terminal capping with hydrophobic residues revealed the importance of both hydrophobicity 113 
and helicity on the anti-mycobacterial activity, with I(LLKK)2I emerging as the most selective 114 
peptide.17 These synthetic α-helical peptides primarily targeted the mycobacterial membrane, 115 
inducing rapid membrane permeabilisation and depolarization, resulting in leakage of 116 
intracellular contents. In this study, the effect of various unnatural amino acid substitutions on 117 
the anti-mycobacterial properties of the peptide, I(LLKK)2I, were investigated. Peptide 118 
secondary structures were assessed by circular dichroism (CD) spectroscopy, while 119 
cytotoxicity was evaluated against human red blood cells and the murine macrophage RAW 120 
264.7 cell line. Antimicrobial activities were studied against a panel of six mycobacterial 121 
strains using the broth microdilution method. The stability of the modified peptides was also 122 
evaluated against the serine protease trypsin. Since M. tuberculosis is a major intracellular 123 
pathogen, the ability of peptides to activate macrophages and eliminate intracellular 124 
mycobacteria was also examined. Finally, the in vitro anti-mycobacterial mechanisms were 125 
studied using confocal and time-lapse fluorescence microscopy. 126 
 127 
Material and methods 128 
 129 
Materials  130 
 131 
Synthetic peptides, including the N-terminal FITC-labeled II-D, were synthesized by GL 132 
Biochem (Shanghai, China) and their purity was confirmed to be more than 95% by reverse-133 
phase HPLC. DMEM, PBS solution, DMSO, rifampicin, moxifloxacin, Tween 80, glycerol, 134 
propidium iodide, HPLC grade water, Triton X-100 and lipopolysaccharides (LPS) from 135 
Escherichia coli 0111:B4 were from Sigma-Aldrich (St Louis, MO, USA). Hygromycin B was 136 
from Roche Diagnostics (Indianapolis, IN, USA). FBS was obtained from Labtech 137 
International (Sussex, UK). Difco Middlebrook 7H9 broth, Difco Mycobacteria 7H11 agar, 138 
BBL Middlebrook albumin-dextrose catalase (ADC) supplement, and OADC were from BD 139 
(Sparks, MD, USA). MTT was from Duchefa Biochemie (Haarlem, Netherlands), while the 140 
membrane dye FM4-64FX was from Molecular Probes, Inc (Eugene, OR, USA). N-tosyl-L-141 
phenylalanyl chloromethyl ketone (TPCK)-treated trypsin was from AB Sciex (Framingham, 142 
MA, USA). The mouse TNF-α ELISA Ready-SET-Go kit was from eBioscience (San Diego, 143 
CA, USA) and Griess Reagent System from Promega (Madison, WI, USA). 144 
 145 
Mycobacterial strains and growth conditions  146 
 147 
M. tuberculosis H37Rv (H37Rv) was from ATCC (USA) while M. bovis BCG lux (BCG), 148 
Montreal strain, was transformed with the reporter plasmid construct pSMT1 as previously 149 
described.18 mCherry-expressing BCG (BCG-mCherry) was produced by transforming M. 150 
bovis BCG Danish strain 1331 (Statens Serum Institut) with pCherry3 (Addgene plasmid 151 
#24659 encoding mCherry and conferring hygromycin resistance19) using established 152 
protocols for mycobacteria.20 The MDR clinical isolate, M. tuberculosis CSU87 (CSU87), 153 
resistant to rifampicin, isoniazid, ethambutol, streptomycin and kanamycin, was also evaluated 154 
in this study. Three other clinical isolates were M. tuberculosis 173 (Mtb 173) from the Euro-155 
American lineage and, M. tuberculosis 212 (Mtb 212) and M. tuberculosis 411 (Mtb 411), both 156 
from the East Asian/Beijing lineage. Liquid cultures of all mycobacterial strains were grown 157 
in Middlebrook 7H9 broth supplemented with 0.05% Tween 80, 0.2% glycerol and 10% ADC. 158 
Mycobacterial colonies were grown on solid media consisting of Middlebrook 7H11 agar 159 
supplemented with 0.5% glycerol and 10% OADC. BCG and BCG-mCherry were grown in 160 
7H9 broth or 7H11 agar in the presence of 50 µg/mL hygromycin. Bacterial stocks, grown to 161 
log phase, were prepared in 15% glycerol and aliquots frozen at -80oC.  For each experiment a 162 
fresh vial was defrosted, inoculated into 7H9 broth (as described above) and grown at 37oC in 163 
a shaking incubator (180rpm) until the culture reached mid-log phase.  164 
 165 
Peptide characterization  166 
 167 
Surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy (SELDI-TOF 168 
MS) was performed to confirm the molecular weights of the synthetic peptides. ProteinChip® 169 
NP20 arrays (Bio-Rad Laboratories) were primed with 5 µL of HPLC grade water, and 5 µL 170 
of each peptide (0.5 mg/mL) was applied to the array surface and allowed to air-dry for 1 h at 171 
room temperature. The arrays were washed twice with 5 µL of HPLC grade water and allowed 172 
to air-dry for another 15 min at room temperature. 20% α-cyano-4-hydroxycinnamic acid 173 
(CHCA) was applied twice (2 × 0.7 µL) to each spot on the arrays, allowing the matrix to air-174 
dry between each application. Time-of-flight spectra were generated using a PCS 4000 SELDI-175 
TOF MS instrument (Bio-Rad Laboratories). Spectra from the peptide pools were obtained at 176 
a laser energy of 800 nJ, a focus mass based on the theoretical molecular weight of each 177 
individual peptide and the matrix attenuated to 500 Da. Ten shots were obtained per position 178 
and a total of 500 shots kept per array. Mass accuracy was calibrated externally using All-in-179 
One Peptide (Bio-Rad Laboratories).  180 
 181 
Circular Dichroism (CD) spectroscopy  182 
 183 
CD spectra were recorded at room temperature with Chirascan™ CD Spectrometer (Applied 184 
Photophysics, Surrey, UK). Peptides were first prepared at a final concentration of 0.2 mg/mL 185 
by dissolving them in 25 mM sodium dodecyl sulfate surfactant. Peptide solutions were then 186 
added to a quartz cell with a path length of 1.0 mm and measurements were taken from a 187 
wavelength of 190 to 240 nm, at a scanning speed of 60 nm min-1 and averaged from 3 runs 188 
per peptide. The acquired spectra were converted to mean residue ellipticity using the following 189 
equation:  190 
θ" = 	θ%&'10 ⋅ M,-c ⋅ 𝑙  191 
 192 
where θM is the mean residue ellipticity (deg cm2 dmol-1), θobs is the observed ellipticity 193 
corrected for the blank at a given wavelength (mdeg), MRW is residue molecular weight 194 
(MW/number of amino acids), c is peptide concentration (mg/mL), and 𝑙	is the path length (cm).  195 
 196 
Minimum inhibitory concentration (MIC) measurements  197 
 198 
The anti-mycobacterial activities of the synthetic peptides, and rifampicin and moxifloxacin 199 
were assessed using the standard broth microdilution method. Briefly, two-fold serial dilutions 200 
of the drugs were prepared with 7H9 broth before adding 100 µL to each well of the 96-well 201 
plate. Mid-log phase bacterial cultures were diluted to a density of 106 cfu/mL and an equal 202 
volume was seeded into each well. The plates were then incubated at 37oC in a shaking 203 
incubator and read after 7 days. The MIC was defined as the lowest concentration with no 204 
bacterial growth, determined both visually and by spectrophotometric measurements taken 205 
with the iMark™ Microplate Absorbance Reader (Bio-Rad Laboratories, Hertfordshire, UK) 206 
at OD595. Experiments were carried out in triplicate on 2 or 3 separate occasions. 207 
 208 
Haemolytic activity test  209 
 210 
Synthetic peptides were assessed for toxicity against mammalian cells using freshly drawn red 211 
blood cells (RBCs) from healthy adult donors. Prior to commencement, ethical approval was 212 
granted from Imperial College London NHS Healthcare Tissue Biobank (sub-collection 213 
reference number: Pae-SN-15-001) and written informed consent was obtained from all 214 
participants. Haemolytic activity was tested on a 4% (v/v) suspension obtained by a 25x 215 
dilution of RBCs with PBS. Peptides were serially diluted with PBS to give solutions with final 216 
concentrations ranging from 0 to 1000 mg/L. Equal volumes of peptide solution and blood 217 
suspension were then mixed to give a final volume of 600 µL. Following incubation at 37oC 218 
for 2 h, the mixtures were centrifuged at 1700 g for 5 min. 100 µL of the supernatant was then 219 
added to each well of the 96-well plate and haemoglobin release was measured 220 
spectrophotometrically at 576 nm by the VersaMax Tunable microplate reader (Molecular 221 
Devices, Sunnyvale, CA, USA). Untreated RBCs were included as the negative control while 222 
RBCs treated with 1% Triton X-100 served as the positive control. Data are expressed as mean 223 
± standard deviation for two independent runs performed in triplicate. The degree of 224 
haemolysis was calculated using the following equation: 225 𝐻𝑎𝑒𝑚𝑜𝑙𝑦𝑠𝑖𝑠	 % = (:;<=>?@	AB	CDEFCEG	HFIJKEL:;<=>?@	AB	MENFCOPE	QAMCDAK)(:;<=>?@	AB	JAHOCOPE	QAMCDAKL:;<=>?@	AB	MENFCOPE	QAMCDAK) ×	100%  226 
 227 
In vitro killing efficiency test  228 
 229 
The antimicrobial peptide II-D was evaluated for its ability to kill H37Rv and clinical isolates 230 
Mtb 411 and CSU87, as it possessed the highest selectivity for bacterial over mammalian cells. 231 
Peptides were serially diluted with 7H9 broth to give solutions with final concentrations 232 
ranging from 31.3 to 500 mg/L. 100 µL of diluted bacterial culture, with an inoculum size of 233 
106 cfu/mL, was added to an equal volume of peptide solution. Following 7 days of incubation 234 
at 37oC in a shaking incubator, samples were serially diluted in PBS and 10 µL was plated out 235 
in duplicates onto 7H11 agar. Bacterial colonies were counted after incubation at 37oC for 14 236 
days. Experiments were carried out on at least 2 separate occasions and results are expressed 237 
as mean log (cfu/mL) ± standard deviation of both runs. 238 
 239 
Cell culture and cytotoxicity testing  240 
 241 
Peptides were evaluated for their cytotoxicity against the mouse macrophage cell line RAW 242 
264.7 using the MTT assay. RAW 264.7 cells were maintained in DMEM supplemented with 243 
10% FBS and cultured in humidified atmosphere at 37oC and 5% CO2. The cells were first 244 
seeded at a density of 1 x 104 per well in 96-well plates and allowed to incubate for 24 h. Cells 245 
were then treated with peptides solutions ranging from 1.95 to 250 mg/L for an additional 24 246 
h. Subsequently, the medium was replaced with 200 µL of fresh DMEM and 40 µL MTT 247 
solution (5 mg/mL) and incubated for another 4 h at 37oC. The resultant formazan crystals were 248 
then dissolved using 150 µL DMSO and absorbance was measured spectrophotometrically at 249 
595 nm in a VersaMax Tunable microplate reader (Molecular Devices, Sunnyvale, CA, USA). 250 
Cell viability was determined relative to untreated controls and expressed 251 
as	 𝐴UVUMI	of	treated	sample /(𝐴UVUMI	of	control)×100%. Data are expressed as mean ± 252 
standard deviation for two independent runs performed in triplicate. 253 
 254 
Intracellular anti-mycobacterial activity  255 
 256 
The intracellular activity of the antimicrobial peptide II-D was assessed against M. tuberculosis 257 
clinical isolates Mtb 411 and CSU87 as described previously.21 Briefly, RAW 264.7 cells were 258 
plated at a final concentration of 4 x 104 per well in 96-well plates and incubated for 24 h to 259 
allow for adherence. Prior to infection, mid-log phase bacterial cultures were washed twice 260 
with PBS, resuspended in DMEM and added at a final concentration of 4 x 105 cfu per well to 261 
achieve a multiplicity of infection (MOI) of 10:1. Plates were incubated at 37oC and 5% CO2 262 
for 4 h to allow for uptake of bacteria by macrophages. Subsequently, cells were washed thrice 263 
with prewarmed DMEM to remove extracellular bacteria before adding 200 µL of DMEM, 264 
with or without drugs, to each well. II-D was tested at concentrations corresponding to 0.5x, 265 
1x, 2x and 4x MIC, while rifampicin and moxifloxacin were evaluated at 1x, 2x, 4x and 8x 266 
MIC. Each concentration was tested in triplicate. For determination of bacterial viability at 267 
various time points, macrophages were lysed with 200 µL of sterile water for 30 min, serially 268 
diluted with PBS and 10 µL was plated out in duplicate on 7H11 agar. Following incubation at 269 
37oC for 14 days, bacterial colonies were enumerated and data are expressed as mean log 270 
(cfu/mL) ± standard deviation. 271 
 272 
Nitric oxide (NO) production by peptide-treated macrophages  273 
 274 
RAW 264.7 cells were seeded in 96-well plates at a density of 4 x 104 per well, followed by 275 
incubation at 37oC and 5% CO2 for 24 h. The medium was removed and cells were treated with 276 
peptide solutions ranging from 7.81 to 250 mg/L for an additional 24 h. NO production was 277 
estimated by measuring nitrite concentrations in supernatants using the Griess reagent (0.1% 278 
N-1-napthylethylenediamine dihydrochloride, 1% sulfanilamide and 5% phosphoric acid) 279 
according to the manufacturer’s protocols. The absorbance was measured by at 540 nm and 280 
nitrite concentrations were determined using standard curves generated with NaNO2 solutions. 281 
Macrophages stimulated with 100 ng/mL LPS served as positive controls while unstimulated 282 
macrophages served as negative controls. Data are expressed as mean ± standard deviation for 283 
two independent runs performed in triplicate. 284 
 285 
TNF-α production by peptide-treated macrophages  286 
 287 
RAW 264.7 cells were seeded in 96-well plates at a density of 4 x 104 per well, followed by 288 
incubation at 37oC and 5% CO2 for 24 h. The medium was removed and cells were treated with 289 
peptides solutions ranging from 7.81 to 250 mg/L for an additional 24 h. TNF-α concentration 290 
in supernatants was determined using the mouse TNF-α ELISA kit as per the manufacturer’s 291 
instructions. Absorbance readings were measured at 450 nm. Unstimulated macrophages 292 
served as negative controls, and positive controls were stimulated with 100 ng/mL LPS. Data 293 
are expressed as mean ± standard deviation for two independent runs performed in triplicate. 294 
The degree of TNF-α production was calculated as follows: 295 𝑇𝑁𝐹 − 𝛼	𝑝𝑟𝑜𝑑𝑢𝑐𝑡𝑖𝑜𝑛	 % = (:;p<q?@	AB	CDEFCEG	HFIJKEL:;p<q?@	AB	MENFCOPE	QAMCDAK)(:;p<q?@	AB	JAHOCOPE	QAMCDAKL:;p<q?@	AB	MENFCOPE	QAMCDAK) ×	100%  296 
 297 
Protease stability assay 298 
 299 
The proteolytic stability of the synthetic peptides was assessed by measuring their 300 
antimicrobial activity against BCG after pretreatment with the serum protease, trypsin, in 301 
accordance with methods described previously.12 Briefly, peptide solutions at a fixed 302 
concentration of 4x MIC were incubated with trypsin at an enzyme to peptide ratio of 1:100. 303 
Following incubation at 37oC for 6 h, the solutions were heat-treated at 80oC for 10 min to 304 
inactivate the enzyme. 100 µL of the treated peptide solution was then added to an equal 305 
volume of bacterial culture (106 cfu/mL) and incubated at 37oC in a shaking incubator for 7 306 
days. Inhibition of bacterial growth was determined by spectrophotometric measurements at 307 
OD595. Data are expressed as mean ± standard deviation for two independent runs performed 308 
in triplicate. 309 
 310 
Microfluidic live-cell imaging with time-lapse fluorescence microscopy  311 
 312 
Live-cell imaging was performed using the automated CellASIC ONIX Microfluidic Platform 313 
with the CellASIC ONIX B04A-03 Microfluidic Bacteria Plates (EMD Millipore Corporation, 314 
Hayward, CA, USA). Mid-log phase cultures of BCG were first diluted with 7H9 broth to a 315 
final density of 107 cfu/mL, before adding 100 µL to each of the cell loading wells. To evaluate 316 
the antimicrobial mechanisms of action, the most selective peptide II-D, was serially diluted 317 
with 7H9 broth to give final concentrations corresponding to 4x and 8x MIC. Peptide solutions 318 
were then added to the inlet wells together with the membrane-impermeable dye, propidium 319 
iodide (10 µg/mL), in a total volume of 350 µL. Next, the microfluidic plate was vacuum-320 
sealed to the F84 manifold and the CellASIC ONIX FG Software initiated. Loading and 321 
subsequent washing of un-trapped bacterial cells was carried out according to the 322 
manufacturer’s protocol.22 Peptide solutions were perfused into culture chambers at the 323 
recommended pressure of 2 psi for up to 4 h. The temperature was maintained at 37oC and 324 
bacterial cells treated with medium and propidium iodide alone served as negative controls. 325 
Phase contrast and fluorescent images of bacterial cells were captured with a 63x oil-immersion 326 
objective lens every 10 min using the Zeiss Axiovert 200M inverted microscope (Carl Zeiss 327 
Inc.). Microscopy was performed in the Facility for Imaging by Light Microscopy (FILM) at 328 
Imperial College London. 329 
 330 
Confocal laser-scanning microscopy  331 
 332 
BCG and BCG-mCherry cultures were grown up to mid-log phase, centrifuged at 2000 g for 333 
10 min, washed, and resuspended in PBS at a cell density of 108 cfu/mL. Following treatment 334 
with 500 mg/L FITC-labelled II-D for 2 h, bacterial cells were centrifuged at 2000 g for 10 min 335 
and washed three times with PBS. To stain bacterial membranes, BCG cells were resuspended 336 
in PBS with 2 µg/mL FM4-64 for 10 min at 37oC with shaking. Cells were then pelleted, 337 
washed twice with PBS to remove any unbound dye, and fixed overnight with 4% 338 
formaldehyde at 4oC. Following fixation, cells were pelleted, resuspended in PBS and allowed 339 
to air dry on microscope slides for 20 min. Samples were mounted with Mowiol mounting 340 
medium and imaged with a 100x oil-immersion objective lens using a Zeiss LSM-510 inverted 341 
confocal microscope (Carl Zeiss Inc.). FITC was excited with a 488 nm laser and detected with 342 
a 505-530 nm band-pass filter while mCherry and FM4-64 were both excited with a 543 nm 343 
laser and detected with a 615 nm and 650 nm long-pass filters respectively. 344 
 345 
Image and statistical analysis  346 
 347 
The Huygens Deconvolution software (Scientific Volume Image) was used to perform 348 
deconvolution of confocal images. Fluorescence intensity profiles along the bacterial cell 349 
length were obtained with the segmented line and multi-channel intensity line profile plot tools 350 
in the ImageJ software. Processing and compiling of phase and fluorescent images into movies 351 
at 2 frames per second, were carried out using the ImageJ software. All statistical analysis in 352 
this study was performed with GraphPad Prism 6 software (GraphPad Software Inc., CA, USA) 353 
using one-way analysis of variance (ANOVA), with Bonferroni’s post hoc test for multiple 354 
comparisons. Significant differences between groups were indicated as follows: * p ≤ 0.05, ** 355 
p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001.  356 
 357 
Results and discussion 358 
 359 
Peptide design and characterization 360 
 361 
We previously reported that short 10 amino acid peptides with the backbone sequence 362 
X(LLKK)2X (where X is a hydrophobic amino acid), assumed ordered α-helical conformations 363 
in a membrane-mimicking environment and were capable of eradicating mycobacteria in 364 
vitro.16, 17 In this study, systematic substitutions with unnatural or D-amino acids were 365 
performed in an attempt to design synthetic analogues with improved stability and selectivity 366 
indices. The isoleucine substituted analogue, I(LLKK)2I or II, which emerged as one of the 367 
most selective peptides against mycobacteria, served as a framework for these structural 368 
modifications. To maintain sequence identity and structural integrity of the optimized lead 369 
peptide, the two main modifications involved (a) swapping all L-amino acid with D-amino acid 370 
residues and (b) substitution of lysine (Lys) residues with Lys analogues possessing shorter 371 
side-chains including ornithine (Orn), 2,4-diaminobutyric acid (Dab) or 2,3-diaminopropionic 372 
acid (Dap). The C-terminal of all synthetic analogues was amidated to improve anti-373 
mycobacterial activity by increasing net positive charge.23 The sequences and abbreviated 374 
names of the five synthetic peptides evaluated in this study are listed in Table 1. In order to 375 
verify that the peptides were successfully synthesized according to the desired specifications, 376 
SELDI-TOF MS was performed for molecular weight determination. As shown in Table 1, the 377 
close agreement between the theoretical and measured molecular weights of the peptides 378 
served as confirmation of the fidelity of peptide synthesis.  379 
 380 
Circular Dichroism spectroscopic studies 381 
 382 
The influence of unnatural or D-amino acid substitutions on the secondary conformation of the 383 
synthetic peptides was investigated in a membrane-like environment consisting of 25 mM SDS 384 
micelle solution, and studied using CD spectroscopy. The CD spectra of the synthetic peptides 385 
are summarized in Figure 1. The presence of the characteristic absorption bands at ~208 and 386 
222 nm suggests that all five synthetic peptides adopted α-helical structures in 25 mM SDS. 387 
The replacement of Lys residues with Orn, Dab or Dap, did not compromise the helical 388 
structure of peptides, evident from the comparable relative helicities and mean residue 389 
ellipticity values at 222 nm (θ222) as shown in Table 1. As expected, II-D exhibited a CD 390 
spectrum of opposite sign to that of II, though not an exact mirror image. II-D recorded a lower 391 
absolute θ222 value than II (10033 versus 11290), indicative of a slight reduction in α-helical 392 
conformation. Since, D-allo-isoleucine was utilised during peptide synthesis, the observed 393 
differences in CD ellipticity at 222 nm could be attributed to II and II-D being diastereomers, 394 
rather than enantiomers of each other.24 395 
 396 
In vitro anti-mycobacterial activity 397 
 398 
The antimicrobial activities of the synthetic helical peptides were evaluated by the broth 399 
microdilution method against a panel of six mycobacterial strains and the results are 400 
summarized in Table 2. Overall, structural modifications with unnatural or D-amino acids were 401 
effective in producing analogues with improved anti-mycobacterial activities. A two to 402 
fourfold reduction in the geometric mean (GM) of the MICs was observed for the modified 403 
peptides as compared to II. Importantly, three of the synthetic peptides displayed a fourfold 404 
reduction in MIC in comparison to II against the MDR clinical isolate CSU87. The replacement 405 
of Lys with Orn proved least effective, with II-Orn demonstrating similar activity as II against 406 
50% of the mycobacterial strains tested. This analogue was more active against only two of the 407 
six strains, while substitution of Lys with Dab and Dap resulted in decrease in MICs against 408 
five and four of the six strains respectively. The all D-amino acid analogue exhibited superior 409 
efficacy as compared to II against all six mycobacterial strains, which translated into a fourfold 410 
reduction in the GM of its MICs.  411 
We had previously reported that both hydrophobicity and folding of peptides into amphipathic 412 
helical structures was crucial for inducing mycobacterial membrane permeabilisation and 413 
augmenting anti-mycobacterial activity.17 Given that II and II-D are diastereomers of each 414 
other, their amino acid composition, charge, molecular weight, amphiphilicity and in turn 415 
hydrophobicity is expected to be similar. However, the lower relative helicity of 0.89 for II-D 416 
(Table 1) as compared to II would be expected to compromise its activity, but the converse was 417 
true. The reduced hydrophobicities of II-Orn, II-Dab and II-Dap relative to that of II, also did 418 
not translate into diminished activities. This suggests that factors unrelated to the 419 
physiochemical properties of the peptides may also be responsible for the observed differences 420 
in anti-mycobacterial efficacy of the synthetic peptides. A plausible explanation is that the 421 
structural modifications employed in this study could potentially have enhanced peptide 422 
stability to extracellular proteolytic enzymes of M. tuberculosis, in turn rendering them more 423 
active against the pathogen. M. tuberculosis culture filtrates containing proteases were found 424 
to diminish the anti-tubercular activity of the L- rather than D-enantiomer of peptides, with the 425 
latter demonstrating greater resistance to degradation, evident from the significantly higher 426 
recovery as compared to the L-enantiomer (89% versus 26%) after 7 days exposure.15 These 427 
findings suggest that stability-enhancing modifications such as the incorporation of unnatural 428 
amino acids may be crucial to developing AMPs with superior efficacies against slowly-429 
replicating bacilli like M. tuberculosis. 430 
 431 
Haemolytic activities, cytotoxicity and cell selectivities  432 
 433 
The haemolytic activities of the synthetic peptides were evaluated using 4% (v/v) human blood 434 
from two healthy adult donors and the results are summarized in Figure 2(a). Even at the 435 
highest tested concentration of 1000 mg/L, all five peptides displayed minimal haemolysis of 436 
approximately 2%. The HC50 values, defined as the lowest peptide concentration resulting in 437 
50% haemolysis of RBCs, of all five peptides was found to be >1000 mg/L (Table 2). Similar 438 
observations were also made with respect to the cytotoxicity of the peptides against the murine 439 
macrophage cell line, RAW 264.7. As highlighted in Figure 2(b), cell viabilities remained in 440 
excess of 80% even at concentrations of 250 mg/L following 24 h exposure to synthetic 441 
peptides. Importantly, none of the modifications produced analogues of II with an inferior 442 
toxicity profile against mammalian cells. The selectivity indices (SIs) highlighted in Table 2, 443 
defined as the ratio of HC50 to GM MIC values, are often utilised to identify analogues with 444 
superior antibacterial selectivities. The D-amino acid analogue of II emerged as the most 445 
selective for mycobacterial over mammalian cells, with a SI value of 20. This was fourfold 446 
greater than that of II and approximately 1.8 and 2.2 times higher than that of II-Dab and II-447 
Dap respectively. Since larger SI values are deemed as more desirable, the strategies presented 448 
in this study could therefore prove useful in designing more selective AMPs to treat M. 449 
tuberculosis infections.  450 
 451 
Resistance to protease degradation  452 
 453 
A major barrier limiting the clinical application of AMPs is their susceptibility to protease 454 
degradation in biological fluids.8 Trypsin specifically cleaves the C-terminal of both lysine and 455 
arginine, thus, peptides containing these cationic residues are likely to be rendered inactive. 456 
We therefore assessed the stability of the Lys-rich II and its unnatural amino acid substituted 457 
analogues by pre-treating the peptides with trypsin before evaluating their antimicrobial 458 
activities against BCG using the standard broth microdilution method. As shown in Figure 2(c), 459 
all five peptides inhibited bacterial growth after 7 days when no prior treatment with trypsin 460 
was performed. However, following pre-treatment with trypsin, the antimicrobial activity of 461 
only II was lost while that of the other four modified peptides was preserved. The modifications 462 
to II not only produced analogues with superior mycobacterial selectivity (Table 2), but also 463 
conferred protection against the serine protease trypsin, enhancing their clinical utility.  464 
 465 
In vitro and intracellular killing efficiencies  466 
 467 
The D-amino acid analogue of II was not only more resistant to enzymatic degradation, but 468 
also exhibited the highest SI of all peptides evaluated in this study. Hence, II-D was evaluated 469 
for its in vitro killing efficiency against laboratory strain H37Rv, the drug-susceptible clinical 470 
isolate Mtb 411, and the MDR clinical isolate CSU87. II-D displayed killing efficiencies of 471 
>90% at the respective MICs for all three strains (Figure S1). At 2x the respective MIC values, 472 
II-D killing efficiency was >99% against both H37Rv and CSU87 and >97% against Mtb 411. 473 
The intracellular activity of II-D was subsequently evaluated against both drug-susceptible and 474 
MDR clinical isolates of M. tuberculosis during macrophage infection, at concentrations 475 
corresponding to 0.5x, 1x, 2x and 4x MIC. The first-line anti-tubercular drug, rifampicin, and 476 
second-line fluoroquinolone, moxifloxacin, served as controls for Mtb 411 and CSU87, 477 
respectively. As shown in Figures 3(a) and 3(b), II-D and rifampicin resulted in significant 478 
reductions in intracellular Mtb 411 counts following 4-day treatment as compared to untreated 479 
controls (p < 0.0001). Both II-D and rifampicin demonstrated concentration-dependent killing 480 
of Mtb 411, although peptide treatment was more effective in rapidly eliminating the 481 
intracellular pathogen. At their respective MICs, rifampicin and II-D reduced bacillary loads 482 
within 3 days by 36% and 84%, respectively. Furthermore, exposure to II-D at 250 mg/L (4x 483 
MIC) resulted in approximately 1 log reduction of intracellular bacterial burden by days 3 and 484 
4 (Figure 3a). This effect was less pronounced with rifampicin as bacterial counts decreased 485 
by 66% and 70% on days 3 and 4 respectively, even up to concentrations corresponding to 8x 486 
MIC (0.016 mg/L). Similarly, II-D and moxifloxacin also induced significant reductions in 487 
intracellular CSU87 counts after 4 days in comparison to untreated controls (p < 0.0001). II-D 488 
brought about a 62% decrease in bacterial load within 4 days, even at sub-MIC of 31.3 mg/L 489 
(Figure 3c). II-D was also more effective than moxifloxacin in clearing intracellular CSU87 at 490 
equivalent concentrations of 1x, 2x and 4x MIC. Given that II-D demonstrated minimal toxicity 491 
towards RAW 264.7 macrophage cell line, with high cell viability of 90% even up to 492 
concentrations of 250 mg/L (Figure 2b), the observed reductions in intracellular mycobacterial 493 
load were a direct consequence of peptide treatment rather than cytotoxic effects on 494 
macrophages. Overall, these findings reinforce the applicability of AMPs for the treatment of 495 
intracellular pathogens such as M. tuberculosis. 496 
 497 
In vitro and intracellular antimicrobial mechanisms  498 
 499 
The bactericidal activity of AMPs is largely mediated by non-specific membrane-lytic 500 
mechanisms, which induces pore formation and/or membrane destruction, leading to 501 
membrane depolarization and outflow of cytoplasmic contents.4 In this study, the antimicrobial 502 
mechanisms of II-D were investigated against BCG using microfluidic live-cell imaging by 503 
employing the CellASIC™ ONIX Microfluidic Platform. Bacterial cells were treated with 504 
peptides at 4x and 8x MIC, in the presence of the DNA intercalating dye propidium iodide (PI) 505 
for up to 4 h. As illustrated in Movies S1 and S2, exposure of BCG to II-D at 4x and 8x MIC 506 
resulted in fluorescence staining of bacterial cells within 10 min. The uptake of PI was 507 
concentration-dependent, with ~50% of bacterial cells exhibiting fluorescence after 210 min at 508 
8x MIC of II-D (Figure 4) while a much lower proportion of cells were stained over the same 509 
time period at 4x MIC of II-D  (Figure S2). Given the membrane-impermeant nature of PI, the 510 
dye is generally excluded from viable cells with intact bacterial membranes. Hence, the 511 
observed fluorescence provides evidence of the membrane-permeabilising activity of II-D, 512 
resulting in the loss of membrane integrity which in turn facilitates intracellular diffusion and 513 
binding of PI to DNA. Furthermore, II-D demonstrated bactericidal activity at both these 514 
concentrations against BCG with a >2 log reduction in RLU readings after 7 day treatment as 515 
compared to the initial inoculums (Figure S3a). Taken together, these findings suggest that the 516 
bactericidal activity of II-D may partly be mediated by disrupting the structural integrity of the 517 
mycobacterial membrane.   518 
Increasingly, the ability of AMPs to modulate the host innate immunity has been explored as 519 
an alternative strategy for effective infection control.25 To evaluate the capacity of II-D to 520 
modulate host immunity by activating macrophages, unstimulated RAW 264.7 cells were 521 
treated with up to 250 mg/L of the peptide for 24 h and proinflammatory responses were 522 
quantified by analysing NO and TNF-α production relative to that of LPS-stimulated 523 
macrophages. As shown in Figure 5, II-D neither induced NO nor TNF-α production, 524 
suggestive of its inability to effect macrophage activation. Thus, the observed intracellular anti-525 
mycobacterial activity of II-D is likely due to direct bactericidal mechanisms rather than the 526 
induction of secondary proinflammatory responses.  527 
 528 
Cellular localization of II-D  529 
 530 
To ascertain the site of action of II-D, BCG was exposed to FITC-labeled II-D for 2 h using 531 
the CellASIC™ ONIX Microfluidic Platform and its localization was visualized by 532 
fluorescence microscopy. FITC-II-D was tested at 500 mg/L as the killing efficacy against 533 
BCG was similar to that of II-D at 2x MIC (Figures S3b and S3c). As shown in Figure 6(a), 534 
treatment of BCG with 500 mg/L of FITC-II-D resulted in peptide accumulation within the 535 
cytoplasm as evidenced by the bright green fluorescence signal. This was confirmed by 536 
confocal laser-scanning microscopy studies with mCherry-expressing BCG where the co-537 
localization of FITC-II-D with the cytosolic fluorescence protein mCherry was observed 538 
(Figure 6b). Bacterial cells unaffected by FITC-II-D demonstrated strong red fluorescence 539 
signal across the entire cell length without any detectable green fluorescence peptide signal 540 
(Figures 6b, S4b and S4c), while peptide penetration into bacterial cells resulted in stronger 541 
green than red intracellular fluorescence intensity profile along the cell length (Figure S4a). 542 
This observed reduction in red fluorescence mCherry signal in cells which internalized FITC-543 
II-D was likely due to peptide-mediated membrane permeabilisation resulting in leakage of 544 
cytosolic contents.   545 
Next, co-labeling studies with the membrane-binding dye FM4-64 in BCG revealed that the 546 
red FM4-64 signal was predominantly located on the bacterial cell surface, and showed the 547 
same pattern of staining as the green fluorescence of FITC-II-D (Figure 6c). Moreover, the 548 
fluorescence intensity profile of FM4-64 across the cell width matched that of FITC-II-D 549 
(Figures S5a and S5b). Previous studies have reported that the cell-penetrating peptide, buforin 550 
II, accumulates in cytoplasm without inducing the influx of PI into bacterial cells, suggestive 551 
of a non-membrane permeabilising mode of action.26 Following internalization, buforin II 552 
promotes cell death by inhibiting cellular functions through binding strongly to DNA and 553 
RNA.27 In contrast, the membrane-permeabilising α-helical peptide magainin II, binds to the 554 
bacterial membrane, inducing pore formation and promoting the influx of PI.26 In this study, 555 
fluorescence and confocal microscopy analysis revealed that II-D permeates the mycobacterial 556 
cell membrane and accumulated in the cytoplasm (Figure 6). Additionally, membrane integrity 557 
studies with PI provided evidence of the membrane-lytic mechanisms of action (Figure 4). 558 
Taken together, the killing mechanisms of II-D could potentially be attributed to both pore-559 
formation and targeting of intracellular components. Recently, non-membrane lytic, cell-560 
penetrating synthetic AMPs (SAMPs) were reported to selectively kill M. smegmatis by 561 
binding bacterial DNA and consequently inhibiting DNA-dependent processes including 562 
replication and transcription.28 Hence, the ability of the membrane-active peptide II-D to 563 
interact with intracellular targets such as bacterial DNA and RNA warrants further 564 
investigation.  565 
In summary, synthetic helical AMPs modified with unnatural amino acids demonstrated 566 
improved anti-mycobacterial activities and stability to trypsin degradation as compared to the 567 
all L-amino acid peptide, II.  The incorporation of D-amino acids proved to be the most 568 
effective modification, with the diastereomer II-D exhibiting a fourfold increase in SI as 569 
compared to II, likely due to the enhanced stability to M. tuberculosis proteases. In addition to 570 
its in vitro inhibitory activity against both drug-susceptible and MDR M. tuberculosis, II-D 571 
was equally, if not more effective, at clearing intracellular mycobacteria than both rifampicin 572 
and moxifloxacin at MIC equivalent concentrations. Mechanistic studies revealed that the site 573 
of action of II-D may not be limited to the mycobacterial membrane, but could potentially 574 
involve intracellular targets following internalization of the peptide. Overall, these findings 575 
reiterate the importance of unnatural amino acid substitutions towards enhancing protease 576 
stability while highlighting their applicability in designing AMPs with superior mycobacterial 577 
selectivity.  578 
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Tables and Figures 680 
 681 
Table 1. Design of α-helical peptides modified with unnatural amino acids and their 682 
molecular weights. 683 
Antimicrobial 
peptide 
Peptide sequencea Theoretical 
MW 
Measured 
MWb 
 [θ]222c Relative 
helicityd  
II I(LLKK)2I-NH2 1208.67 1209 11290 1.00 
II-D i(llkk)2i-NH2 1208.67 1209 10033 0.89 
II-Orn I(LL-Orn-Orn)2I-NH2 1152.56 1153 11432 1.01 
II-Dab I(LL-Dab-Dab)2I-NH2 1096.70 1097 11081 0.98 
II-Dap I(LL-Dap-Dap)2I-NH2 1040.35 1041 11765 1.04 
 684 
aD-amino acids are represented by lower case letters. Ornithine, 2,4-diaminobutyric acid and 2,3-diaminopropionic acid are 685 
abbreviated as Orn, Dab and Dap respectively.  686 
bMolecular weight (Mw) determined by surface-enhanced laser desorption/ionization time-of-flight mass spectroscopy 687 
(SELDI-TOF MS). 688 
cThe mean residue ellipticity values at 222 nm (θ222) were measured in 25 mM SDS solution by circular dichroism 689 
spectroscopy. 690 
dThe helical content of modified peptides relative to the mean residue ellipticity values at 222 nm of II.   691 
 692 
Figure 1. CD spectra demonstrating α-helical secondary conformations of II and its synthetic 693 
analogues with unnatural amino acid substitutions in 25 mM SDS micelle solution. Data are 694 
expressed as mean of three runs per peptide.     695 
Table 2. Minimum inhibitory concentrations (MICs) and selectivity indices (SIs) of helical 696 
peptides against various mycobacterial strains including drug-susceptible and MDR clinical 697 
isolates of Mycobacterium tuberculosis  698 
Antimicrobial 
peptide 
 
MICa (mg/L) GMb  
(mg/L) 
HC50 
(mg/L) SI
c BCG  H37Rv Mtb 173 Mtb 212 Mtb 411 CSU87 
II 125 500 >500 >500 250 250 397 >1000 5 
II-D 31.3 250 125 250 62.5 62.5 99 >1000 20 
II-Orn 62.5 >500 >500 500 250 250 354 >1000 6 
II-Dab 31.3 >500  500 500 62.5 62.5 177 >1000 11 
II-Dap 62.5 >500 > 500 500 62.5 62.5 223 >1000 9 
Rifampicin 0.001 0.015 0.008 0.004 0.002 >32 0.004 - - 
 699 
aMIC results are representative of 2 to 3 independent experiments. 700 
bThe geometric mean (GM) of the MICs against the 6 mycobacterial strains. A value of 1000 mg/L was used for SI 701 
calculations when no anti-mycobacterial activity at observed at the highest tested concentration of 500 mg/L. 702 
cSelectivity index (SI) is determined as follows: (HC50/GM). When no detectable haemolysis was observed at the highest 703 
tested concentration of 1000 mg/L, a value of 2000 mg/L was used for SI calculations.  704 
 705 
Figure 2. Toxicity profiles of synthetic peptides modified with unnatural amino acids against 706 
(a) human red blood cells and (b) the mouse macrophage cell line RAW 264.7. Peptides 707 
displayed minimal haemolytic activity and cytotoxicity against mammalian cells at various 708 
concentrations tested. (c) Inhibitory activity of synthetic peptides against BCG at 709 
concentrations of 4x MIC following 6 h treatment with trypsin at a ratio of 1:100. Only the 710 
unmodified peptide, II, did not inhibit bacterial growth after 7 days. Data are expressed as mean 711 
and standard deviation for two independent experiments.    712 
 713 
Figure 3. Intracellular killing of the drug-susceptible clinical isolate Mtb 411 by (a) 714 
antimicrobial peptide II-D and (b) rifampicin, and the MDR clinical isolate CSU87 by (c) 715 
antimicrobial peptide II-D and (d) moxifloxacin. One-way ANOVA followed by Bonferroni's 716 
post-hoc test was applied for the determination of significant differences, where * p ≤ 0.05, ** 717 
p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001. Data are expressed as mean and standard deviation 718 
from one representative experiment.  719 
 720 
Figure 4. Time-lapse fluorescence microscopy images of BCG following treatment with 721 
antimicrobial peptide II-D at 8x MIC in the presence of the membrane-impermeable dye, 722 
propidium iodide (PI). Peptide-mediated membrane disruption promoted uptake of PI into 723 
bacterial cells. Scale bar = 10 µm. Images are presented from one representative experiment. 724 
This figure appears in colour in the online version of JAC and in black and white in the printed 725 
version of JAC.  726 
 727 
Figure 5. The ability of antimicrobial peptide II-D to promote (a) nitric oxide (NO) and (b) 728 
tumour necrosis factor-α (TNF-α) production in unstimulated RAW 264.7 mouse macrophage 729 
cells following 24 h treatment. II-D did not induce NO or TNF-α as compared to cells 730 
stimulated with 100 ng/mL LPS, which served as positive controls. Data are expressed as mean 731 
and standard deviation for two independent experiments.   732 
 733 
Figure 6. (a) Fluorescence microscopy images of BCG treated with 500 mg/L FITC-labelled 734 
II-D for 2 h using the CellASIC ONIX Microfluidic Platform. Scale bar = 10 µm (inset scale 735 
bar = 5µm). Confocal laser scanning microscopy images following incubation of 500 mg/L 736 
FITC-labelled II-D for 2 h with (b) BCG-mCherry and (c) BCG in the presence of 2 µg/mL 737 
membrane dye FM4-64. Scale bar = 2 µm. Images are presented from one representative 738 
experiment. This figure appears in colour in the online version of JAC and in black and white 739 
in the printed version of JAC.   740 
